Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05252078 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

Study acronym: ALTER-E005
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2022 to Jun 2, 2022
    • Study sites: 0 to 1
    • Study title revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).
Trial Details
NCT Number NCT05252078
Lead Sponsor Jiangxi Provincial Cancer Hospital
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
(from sponsor)		 Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Diseases, Digestive System Neoplasms, Digestive System Diseases, Neoplasms by Site +3 more
Related terms Carcinoma, Squamous Cell, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Squamous Cell
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov